It is possible that the beneficial effects of the P receptor antagonist, mifepristone, in patients with cancer, though initiated initially with the concept of inhibiting PIBF, could be found following future studies to be related to inhibiting some other substance than the PIBF protein. This evidence concerns the gene PIBF1 and cancer.